Invention Grant
- Patent Title: 5T4-targeting agents and methods
-
Application No.: US16490972Application Date: 2018-03-14
-
Publication No.: US11427645B2Publication Date: 2022-08-30
- Inventor: Richard Harrop
- Applicant: OXFORD BIOMEDICA (UK) LIMITED
- Applicant Address: GB Oxford
- Assignee: OXFORD BIOMEDICA (UK) LIMITED
- Current Assignee: OXFORD BIOMEDICA (UK) LIMITED
- Current Assignee Address: GB Oxford
- Agency: Marshall, Gerstein & Borun LLP
- Priority: GB1704084 20170315,GB1721603 20171221
- International Application: PCT/GB2018/050652 WO 20180314
- International Announcement: WO2018/167486 WO 20180920
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61K35/17 ; C07K14/725 ; C12N5/0783 ; A61P35/00 ; A61K47/68 ; A61P35/02 ; A61K9/00 ; A61K38/17 ; A61K39/395 ; A61K45/06 ; C07K14/705 ; A61K39/00
Abstract:
The present invention relates to immunotherapeutic approaches to treating haematological cancers. In particular the invention relates to a method for treating a haematological cancer by targeting the 5T4 antigen. As such, the invention provides a method for treating haematological cancers comprising administering to a subject a 5T4-targeting agent. The invention also provides a 5T4-specific chimeric antigen receptor (CAR) and uses thereof in treating cancers.
Public/Granted literature
- US20200010560A1 METHOD Public/Granted day:2020-01-09
Information query
